But neladalkib results worsen, and come with a red flag about liver enzyme elevations.

A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.

The restructured biotech’s new lead project enters phase 1.

The company will imminently start its third pivotal trial of PF-08634404.

The company ditches lorigerlimab in prostate cancer.

But the Day One deal is still 29% below where the shares stood at the start of this year.